Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally.
+ 1 more risk
Adequate balance sheet and slightly overvalued.
Share Price & News
How has Bellicum Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BLCM's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: BLCM underperformed the US Biotechs industry which returned 8.9% over the past year.
Return vs Market: BLCM underperformed the US Market which returned 10.2% over the past year.
Price Volatility Vs. Market
How volatile is Bellicum Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StWhat Kind Of Shareholders Own Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)?
1 month ago | Simply Wall StIf You Had Bought Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock Five Years Ago, You'd Be Sitting On A 91% Loss, Today
1 month ago | Simply Wall StHave Insiders Been Buying Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Shares This Year?
Is Bellicum Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BLCM ($8.81) is trading below our estimate of fair value ($185.66)
Significantly Below Fair Value: BLCM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BLCM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: BLCM is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLCM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLCM is overvalued based on its PB Ratio (35.6x) compared to the US Biotechs industry average (3x).
How is Bellicum Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BLCM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BLCM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BLCM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BLCM's revenue (58.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: BLCM's revenue (58.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if BLCM's Return on Equity is forecast to be high in 3 years time
How has Bellicum Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLCM is currently unprofitable.
Growing Profit Margin: BLCM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BLCM is unprofitable, and losses have increased over the past 5 years at a rate of -10.4% per year.
Accelerating Growth: Unable to compare BLCM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLCM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (41.1%).
Return on Equity
High ROE: BLCM has a negative Return on Equity (-484.81%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Bellicum Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: BLCM's short term assets ($104.9M) exceed its short term liabilities ($76.4M).
Long Term Liabilities: BLCM's short term assets ($104.9M) exceed its long term liabilities ($34.7M).
Debt to Equity History and Analysis
Debt Level: BLCM's debt to equity ratio (159.8%) is considered high.
Reducing Debt: BLCM's debt to equity ratio has increased from 19.7% to 159.8% over the past 5 years.
Inventory Level: BLCM has a low level of unsold assets or inventory.
Debt Coverage by Assets: BLCM's debt is covered by short term assets (assets are 2.9x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLCM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: BLCM has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of -20% each year.
What is Bellicum Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate BLCM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BLCM's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BLCM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BLCM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BLCM's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Rick Fair (50yo)
Mr. Richard A. Fair, also known as Rick, serves as Director of Clovis Oncology, Inc since October 11, 2018.served as Chief Executive Officer and President of Bellicum Pharmaceuticals, Inc. since January 31 ...
CEO Compensation Analysis
Compensation vs Market: Rick's total compensation ($USD3.28M) is above average for companies of similar size in the US market ($USD529.87K).
Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.
|Chief Legal & Strategy Officer and Corporate Secretary||1.8yrs||US$1.15m||0.022% $8.7k|
|Chief Financial Officer||1.2yrs||no data||no data|
|Director||0.08yrs||no data||no data|
|Executive Vice President of Technical Operations||4.3yrs||US$1.05m||0.014% $5.6k|
|Head of Research & Senior VP||0.9yrs||no data||0.015% $5.8k|
Experienced Management: BLCM's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|Director||0.08yrs||no data||no data|
|Independent Director||4.6yrs||US$124.47k||no data|
|Chairman of the Board||5.2yrs||US$145.51k||no data|
|Independent Director||3.8yrs||US$103.73k||no data|
|Independent Director||5.2yrs||US$128.79k||no data|
|Member of Scientific & Clinical Advisory Board||0.9yrs||no data||0.19% $74.2k|
|Independent Director||5.3yrs||US$125.66k||no data|
|Independent Director||1.2yrs||US$136.99k||no data|
|Member of Scientific & Clinical Advisory Board||0.9yrs||no data||no data|
Experienced Board: BLCM's board of directors are considered experienced (3.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20%.
Bellicum Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Bellicum Pharmaceuticals, Inc.
- Ticker: BLCM
- Exchange: NasdaqGM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$40.040m
- Shares outstanding: 4.99m
- Website: https://www.bellicum.com
Number of Employees
- Bellicum Pharmaceuticals, Inc.
- Life Science Plaza
- Suite 800
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BLCM||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Dec 2014|
|BPX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2014|
|0HMS||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Dec 2014|
Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also comprise BPX-603, a dual-switch GoCAR-T product candidate to treat solid tumors that express the human epidermal growth factor receptor 2 antigen; BPX-802, a dual switch Go-CAR-T product candidate to treat an antigen expressed in hematological malignancies; and BPX-701, a T cell receptor candidate, which is in Phase I clinical trial for the treatment of malignant cells expressing the preferentially-expressed antigen in melanoma It has collaboration and license agreements with Adaptimmune Therapeutics plc, Ospedale Pediatrico Bambino Gesù, Leiden University Medical Centre, Agensys, Inc., BioVec Pharma, Inc., Leiden University Medical Centre, ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/28 02:22|
|End of Day Share Price||2020/02/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.